CIK 0001636282 · Large accelerated filer
Spyre Therapeutics, Inc.
Sign in to watch- Ticker
- SYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464312787
- Phone
- 6176515940
- Business address
- 221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aeglea BioTherapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,349,597
- in 6 filings, $12.3M under 10b5-1 plans
Net −$12,349,597. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-02 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −100 | $32.39 | $3K | 671,907 |
| 2025-12-01 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −10,995 | $28.73 | $316K | 690,912 |
| 2025-12-01 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −4,005 | $29.83 | $119K | 686,907 |
| 2025-11-03 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −28,155 | $23.13 | $651K | 718,752 |
| 2025-11-03 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −16,845 | $23.66 | $399K | 701,907 |
| 2025-09-02 | Burrows Scott L Chief Financial Officer | Sale | −18,428 | $16.26 | $300K | 97,994 |
| 2025-05-29 | Fairmount Funds Management LLC Director | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2025-05-29 | Fairmount Funds Management LLC Director | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2025-05-29 | Stelzer Laurie Director | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2025-05-29 | Milligan Sandra Director | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2025-05-29 | McKenna Mark C. Director | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2025-05-29 | HENDERSON MICHAEL THOMAS Director | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2025-05-29 | Albers Jeffrey W. Director | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2025-01-15 | Burrows Scott L Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +95,500 | 95,500 | ||
| 2025-01-15 | Sloan Sheldon Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +95,500 | 95,500 | ||
| 2025-01-15 | Turtle Cameron Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +370,000 | 370,000 | ||
| 2025-01-15 | King-Jones Heidy See Remarks | Grant or award · Stock Option (Right to Buy) | +95,500 | 95,500 | ||
| 2025-01-10 | HENDERSON MICHAEL THOMAS Director | Other acquisition | +105,379 | 105,379 | ||
| 2024-11-06 | Albers Jeffrey W. Director | Sale 10b5-1 | −6,700 | $36.76 | $246K | 27,360 |
| 2024-10-25 | Albers Jeffrey W. Director | Sale 10b5-1 | −300 | $36.43 | $11K | 34,060 |
Page 8 of 11 · 213 trades